This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Pascal Renkes, MD; Pierre Gaucher, MD
Service des Maladies de l'Appareil Digestif Nancy, France

Philippe Tréchot, PhD
Service de Pharmacologie Clinique Nancy, France

JAMA. 1995;273(5):376-377.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Spironolactone (Aldactone, G. D. Searle & Co, Skokie, Ill), a diuretic that competitively inhibits aldosterone, has been used worldwide for more than 30 years. Hepatic toxicity from spironolactone is extremely rare; only one case has been reported (by Shuck et al in 1981¹). However, we recently observed another patient with hepatic toxicity from spironolactone in France.

A 74-year-old man treated for 7 weeks with spironolactone (50 mg/d) for moderate edema of the lower limbs was hospitalized on February 26, 1994, when he presented with cutaneous and mucosal icterus. He had no other treatment and no history of liver or biliary system disease or of blood transfusion, and daily alcohol consumption was less than 30 g. Ultrasound of the biliary tree was normal. Results of the liver biopsy showed cholestatic lesions with many biliary thrombi and overloaded centrolobular cells, the hepatocytes were somewhat damaged, and a few . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?